Share this article and save a life!
CMO, can you defend a guideline that would have missed 65% of lung cancer patients? 🔬
Because that is exactly what a new study in JAMA Network Open just showed.
Researchers looked at 89,900 patients diagnosed with lung cancer in South Korea from 2013 to 2018. Then they asked one simple question: how many of these people would have qualified for screening under current international guidelines, including those from the USPSTF, ACS, and NCCN?
The answer should stop every screening program leader in their tracks.
📊 Here is what the data actually showed:
– 65% of lung cancer patients would NOT have been eligible for screening under international guidelines
– 44% had no smoking history at all
– Eligibility by sex: men at 57%, women at just 2.3%
– Never-smokers had 14% lower rates of both all-cause and lung cancer-specific mortality
– Ineligible smokers had 5% lower all-cause mortality and 4% lower lung cancer-specific mortality than eligible smokers
That last point is not a typo. The people we are NOT screening were dying at lower rates than the ones we are. That tells you something important about who we are systematically missing.
This is the structural flaw no one wants to say out loud.
Current criteria were designed to be risk-based, not population-based. That was a deliberate choice to avoid overdiagnosis. I get the logic. But the cost of that choice is now visible in the data: we built a system that filters out the majority of people who get the disease.
👤 From the patient’s perspective: if you are a non-smoking woman in the U.S., you have essentially no path to a covered lung cancer screen. A guideline that sets female eligibility at 2.3% is not a screening program. It is a selective invitation.
🏥 From the provider’s perspective: you are following the guidelines as written. But this study, according to The Imaging Wire, signals that momentum is building toward broader criteria. The question is how quickly those criteria are adopted, and whether they gain traction outside of Asia.
💰 From the payer or health system perspective: the cost math on missed diagnoses is brutal. Late-stage lung cancer treatment costs dwarf early-stage intervention. If your current screening criteria miss two-thirds of the patients who will eventually show up in your system with advanced disease, that is a coverage design problem, not a clinical one.
At Oatmeal Health, we work every day on closing the lung cancer screening gap for underserved populations in the U.S. This study confirms what we see on the ground: the gap is not just about access to the scan. It is about whether the guidelines themselves are drawing the right circle around who gets to be inside.
Save this post if you are building or evaluating a lung cancer screening program. The eligibility criteria conversation is coming, and you will want this data at the table.
The science is pulling toward population-based thinking. Policy needs to catch up.
👉 Follow Jonathan Govette, CEO of Oatmeal Health, for daily healthcare insights on LinkedIn. Deeper dives in The Oatmeal Bite on Substack: https://news.oatmealhealth.com
Share this article and save a life!
Author:
CEO/Co-Founder @ Oatmeal Health | AI Lung Cancer Screening | Almost Became a Doctor | Engineer | Follow to Share What I’ve Learned Along the Way
I help patients get the care they need earlier, preventing late-stage cancer.
That’s been the throughline across three companies and almost 20 years in healthcare. At ReferralMD, we fixed broken referral networks so patients didn’t fall through the cracks. At Oatmeal Health, it’s lung cancer: building the diagnostic and screening infrastructure so the 85% of cases caught too late get caught early instead.
Today as CEO of Oatmeal Health, I lead a team embedding AI into radiology workflows to turn routine lung CT scans into reimbursable cancer risk assessments. We partner with FQHCs to reach underserved communities, and with health systems and payers to make early detection economically sustainable. Think HeartFlow or Cleerly, but for lungs.
Between companies, I advised at Techstars and Plug and Play, mentoring founders building in digital health. That experience shaped how I think about what separates companies that ship from companies that stall: distribution, reimbursement, and clinical trust, not just technology.
I’m a CancerX alumnus, a 3x healthcare founder, and someone who believes the biggest problems in cancer aren’t scientific. They’re operational.
We’re hiring mission-driven builders at Oatmeal Health. If you want to work on something that matters, reach out.
When I’m not working, I’m traveling, mentoring, and keeping up with one very energetic husky. 🐾
Substack – The Oatmeal Bite:
Millions of patients get less care because of who they are, where they live, or how they look. I’m fighting to change that. CEO @OatmealHealth, a startup built for the underserved. The Oatmeal Bite: intel for clinicians, investors, and advocates.
Jonathan Govette
CEO of Oatmeal Health
Substack:
https://oatmealhealthjonathangovette.substack.com/
